Antiviral efficacy of adefovir ester on fatty liver of HBeAg positive patients with chronic hepatitis B
10.3969/j.issn.1006-5725.2015.07.012
- VernacularTitle:脂肪肝对HBeAg阳性慢性乙型肝炎患者应用阿德福韦酯抗病毒疗效的影响
- Author:
Yanling WANG
;
Bing ZHANG
;
Bingqing LI
- Publication Type:Journal Article
- Keywords:
Hepatitis B,chronic;
Adefovir;
Fatty liver
- From:
The Journal of Practical Medicine
2015;(7):1079-1081
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the impact of hepatic steatosis on the outcome of adefovir therapy in chronic hepatitis B patients with HBeAg positive. Methods The medical records of 154 patients who were diagnosed with CHB positive for hepatitis B e antigen (HBeAg) and received adefovir therapy for 24 weeks between January, 2011 and December, 2013 were analyzed retrospectively. Baseline status and virologic response, biochemical response and serology response between patient with (n = 68) and without (n = 86) steatosis who were proven by ultrasound. Both groups were given oral adefovir dipivoxil 10 mg/d for 24 weeks , recovery rate in ALT/AST, negative conversion rate of HBV DNA and HBeAg were recorded and compared. Results Recovery rate in ALT/AST in observation group was 67.7%, which is lower than control group (83.7%), and the difference is significant(P < 0.05). Negative conversion rate of HBV DNA and HBeAg in control group is 81.4%and 83.7%, which is significantly higher than observation group (whose values are 58.8% and 44.1%, P < 0.05). Conclusion Hepatic steatosis has significant impact on the outcome of adefovir treatment.
